Clinical Trials Sponsored by MedImmune LLC

Total 10783 results

MedImmune LLC

Completed

An Observational Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants

Healthy

United States
MedImmune LLC

Completed

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age (CP149)

Respiratory Syncytial Virus Infections | Respiratory Viral Infections | Parainfluenza Virus 3, Human

United States
MedImmune LLC

Completed

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

Malignant Melanoma

United States
MedImmune LLC

Completed

A Post Marking Study to Evaluate the Safety of FluMist in Children

Healthy

United States
MedImmune LLC

Completed

A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545 (CP145)

Chronic Plaque Psoriasis

Canada
MedImmune LLC

Completed

BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

Lymphoma | Leukemia

United States
MedImmune LLC

Completed

Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants

Respiratory Syncytial Virus Infections

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults

Healthy

United States
MedImmune LLC

Completed

Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

Cancer | Graft-Versus-Host Disease

United States
MedImmune LLC

Completed

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

Healthy

United States
MedImmune LLC

Completed

Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

Melanoma | Malignant Metastatic Melanoma

United States
MedImmune LLC

Completed

Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer

Esophagitis | Non-Small Cell Lung Carcinoma | Pneumonitis

United States
MedImmune LLC

Terminated

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Lymphoma | Leukemia | Cancer

United States
MedImmune LLC

Completed

Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk

Severe Respiratory Disease

United States, Canada, Australia, Italy
MedImmune LLC

Completed

Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis

Psoriasis

United States
MedImmune LLC

Completed

Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)

Influenza

Finland
MedImmune LLC
MedImmune Ltd

Completed

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria, Poland, Russian Federation, South Africa, Spain, Estonia, Hungary, Ukraine, Argentina, Chile, Germany, Serbia, Czech Republic, Colombia
MedImmune LLC

Active, not recruiting

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Carcinoma, Non-Small-Cell Lung

United States, Korea, Republic of, Taiwan
MedImmune LLC

Completed

A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors

Advanced Solid Tumors

United States, United Kingdom
MedImmune LLC

Completed

N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

United States, Czechia, Thailand, Germany, Korea, Republic of, Israel, New Zealand, Spain, Taiwan, Japan, Turkey, Hungary, Bulgaria, Mexico, Russian Federation, Colombia, Peru, Poland, Estonia, South Africa, Canada, Australia, Hong... and more
MedImmune LLC

Completed

A Phase 2 Study to Evaluate Immune Responses of FluMist®

Influenza Vaccine

United States
MedImmune LLC

Completed

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

RSV Illness in ≤12 Months of Participants

United States, Chile, New Zealand, Australia, Panama
MedImmune LLC

Completed

A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

Type 2 Diabetes Mellitus

Netherlands, Sweden
MedImmune LLC

Completed

Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Japan
MedImmune LLC

Terminated

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Canada, Japan, Poland, Germany, Hungary, France
MedImmune LLC

Completed

Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants

Part I (SAD) - Healthy Participants | Part II (MAD) - Chronic Obstructive Pulmonary Disease | Part III (J-SD) - Healthy Japanese Participants

United Kingdom
MedImmune LLC

Terminated

A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses

Healthy Volunteers

United Kingdom
MedImmune LLC

Completed

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

Advanced Solid Tumors

United States, Australia
MedImmune LLC

Completed

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer

Spain, United States, Belgium, France, United Kingdom, Canada, Israel, Germany, Hungary, Poland, Bahamas
MedImmune LLC

Completed

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Germany, Spain, Canada, France, Korea, Republic of, Israel, Netherlands, United Kingdom
MedImmune LLC

Withdrawn

Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza

Influenza
MedImmune LLC

Completed

Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes

Type 2 Diabetes Mellitus

Hungary, Germany, United Kingdom
MedImmune LLC

Completed

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Select Advanced Solid Tumors

United States, France, Netherlands
MedImmune LLC

Completed

A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors. (MEDI4276)

HER2 Expressing Breast or Gastric/Stomach Cancers

United States
MedImmune LLC

Completed

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States, United Kingdom, France, Germany
MedImmune LLC

Completed

A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
MedImmune LLC

Completed

A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Recurrent or Metastatic Solid Tumors

United States, Australia
MedImmune LLC

Completed

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

Cancer

United States
MedImmune LLC

Completed

MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. (MEDI-573-1028)

Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

United States
MedImmune LLC

Completed

A Study in Adult Subjects With Select Advanced Solid Tumors

Advanced Solid Tumors

United States
MedImmune LLC

Terminated

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Cancer | Solid Tumors | CTCL

United States, France, Canada
MedImmune LLC

Completed

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

Healthy Volunteers

United States
MedImmune LLC

Completed

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors. (MEDI-575)

Cancer

United States
MedImmune LLC

Completed

Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (D2213C00001)

Atopic Dermatitis

United States, Germany, Canada, Australia, Poland, Japan
MedImmune LLC

Completed

Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States, Poland
MedImmune LLC

Completed

To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

Coronary Artery Disease

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

Respiratory Syncytial Virus (RSV)

United States
MedImmune LLC

Completed

A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children

Healthy

United States
MedImmune LLC

Terminated

Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)

RSV Infection

United Kingdom
MedImmune LLC

Terminated

A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria, Poland, Russian Federation, South Africa, Spain, United Kingdom, Estonia, Hungary, Ukraine, Argentina, Chile, Czechia, Israel, Slovakia, Greece, Germany, Serbia, Colombia, Mexico

3

Subscribe